Table IV.
Rabeprazole Pharmacokinetics in Ten Healthy Volunteers During Rabeprazole Pretreatment Study Days
| Parameter | Treatment B | Treatment C | Geometric mean ratio (90% CI) |
|---|---|---|---|
| Cmax (ng/mL) | 538 ± 210 | 413 ± 150 | 0.755 (0.507–1.12) |
| AUC0–22 (ng/mL*h) | 968 ± 319 | 825 ± 312 | 0.843 (0.694–1.03) |
| AUC0−∞ (ng/mL*h) | 970 ± 320 | 830 ± 311 | 0.847 (0.699–1.03) |
| Tmax (h) | N/A | N/A | N/A |
| CL/F (mL/min/kg) | 5.33 ± 1.88 | 6.34 ± 2.28 | 1.19 (0.978–1.44) |
| t1/2 (h) | 2.57 ± 1.63 | 2.39 ± 1.75 | 0.863 (0.646–1.15) |
No significant differences were observed in rabeprazole pharmacokinetics with the addition of BHCl. Tmax values were unable to be estimated as plasma concentrations were measured at time points relative to dasatinib administration
C max maximum plasma concentration, T max, time to maximum plasma concentration, t 1/2 terminal half-life, AUC area under the plasma concentration-time curve, CL/F oral clearance, N/A not available